MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.2434

Медицинская библиотека · European journal of heart failure · 2022

Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.

Wild Mirjam G, Kreidel Felix, Hell Michaela M, Praz Fabien, Mach Markus, Adam Matti, Reineke David, Ruge Hendrik, Ludwig Sebastian, Conradi Lenard, Rudolph Tanja K, Bleiziffer Sabine, Kellermair Jörg, Zierer Andreas, Nickenig Georg, Weber Marcel, Petronio Anna Sonia, Giannini Cristina, Dahle Gry, Rein Kjell A, Coisne Augustin, Vincentelli André, Dubois Christophe, Duncan Alison, Quarto Cesare, Unbehaun Axel, Amat-Santos Ignacio, Cobiella Javier, Dumonteil Nicolas, Estevez-Loureiro Rodrigo, Fumero Andrea, Geisler Tobias, Lurz Philipp, Mangieri Antonio, Monivas Vanessa, Noack Thilo, Franco Luis Nombela, Pinon Miguel A, Stolz Lukas, Tchétché Didier, Walter Thomas, Unsöld Bernhard, Baldus Stephan, Andreas Martin, Hausleiter Jörg, von Bardeleben Ralph S, TENDER Investigators

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort.

METHOD AND

RESULTS

All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 ± 7 years, mean STS-PROM 7.2 ± 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to ≤1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30-day all-cause mortality was 12%. At early clinical follow-up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, p < 0.001), and tricuspid regurgitation severity (p = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, p < 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off-label indication (74% vs. 81% for off- vs. on-label, p = 0.41).

CONCLUSION

In a real-world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement.

Для цитирования: Wild Mirjam G, Kreidel Felix, Hell Michaela M, Praz Fabien, Mach Markus, Adam Matti, Reineke David, Ruge Hendrik, Ludwig Sebastian, Conradi Lenard, Rudolph Tanja K, Bleiziffer Sabine, Kellermair Jörg, Zierer Andreas, Nickenig Georg, Weber Marcel, Petronio Anna Sonia, Giannini Cristina, Dahle Gry, Rein Kjell A, Coisne Augustin, Vincentelli André, Dubois Christophe, Duncan Alison, Quarto Cesare, Unbehaun Axel, Amat-Santos Ignacio, Cobiella Javier, Dumonteil Nicolas, Estevez-Loureiro Rodrigo, Fumero Andrea, Geisler Tobias, Lurz Philipp, Mangieri Antonio, Monivas Vanessa, Noack Thilo, Franco Luis Nombela, Pinon Miguel A, Stolz Lukas, Tchétché Didier, Walter Thomas, Unsöld Bernhard, Baldus Stephan, Andreas Martin, Hausleiter Jörg, von Bardeleben Ralph S, TENDER Investigators. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.. European journal of heart failure. 2022. DOI: 10.1002/ejhf.2434.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.